Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Ascendis Pharma stock tanks on earnings miss

Published 09/04/2024, 03:02 AM
© Reuters.
ASND
-

Investing.com -- Shares of Ascendis Pharma (NASDAQ:ASND) dropped in post-market hours on Wednesday following the company’s second-quarter earnings report, which fell short of analysts' estimates.

Ascendis Pharma's stock plunged in after-hours trading, down 18% by 3:03 am (0703 GMT)

The Denmark-based company reported a net loss that narrowed to €109.4 million, from €121.4 million in the same quarter last year.

“We increase GTN (gross to net) in our model starting from Q2'24, lowering our PT to $174,” said analysts at Jefferies in a note.å

“For Yorvipath, we remain positive for its US launch. TransCon CNP's data now expected in Q3'24 and Q1'25 for combo, which could expand ASND's product portfolio,” the analysts said.

Revenue for the quarter dropped by 24% to €36 million. 

“​​Results in the quarter were primarily impacted by a negative adjustment to prior periods’ estimates and assumptions for sales deductions of €27.1 million, where €19.5 million and €7.6 million were attributable to the three months ended March 31, 2024, and periods prior to January 1, 2024, respectively,” the company said in a statement. 

Separately, Ascendis Pharma announced a $150 million capped synthetic royalty funding deal with Royalty Pharma of New York, tied to U.S. sales of Yorvipath, a treatment for hypoparathyroidism in adults.

Under the agreement, Ascendis will receive an upfront payment of $150 million in exchange for a 3% royalty on U.S. net sales of Yorvipath.

Royalty payments to Royalty Pharma will terminate once the payments reach a multiple of 2x, or 1.65x if Royalty Pharma receives that amount by December 31, 2029.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.